Erschienen in:
15.02.2019 | Editorial
Diagnostic performance of F18 FDG PET in cardiac sarcoidosis: Are we getting closer to the truth?
verfasst von:
Hayan Jouni, MD, Panithaya Chareonthaitawee, MD
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 6/2020
Einloggen, um Zugang zu erhalten
Excerpt
Sarcoidosis is a multi-systemic disease traditionally characterized by the presence of non-caseating granulomas. Cardiac sarcoidosis (CS) affects at least 25% of patients with systemic sarcoidosis and is associated with considerable morbidity and mortality.
1 Advanced cardiovascular imaging techniques including Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance imaging have become pivotal in the diagnosis, management, and prognostication of patients with CS.
1,
2 However, studies utilizing advanced imaging to improve the identification and management of CS are limited by a multitude of factors, particularly the small sample sizes and observational nature. Given the fact that larger-scale studies are unlikely to be conducted for this less common disease, meta-analyses have been published to address the diagnostic performance of FDG PET for the detection of CS.
3 Since the first meta-analysis by Youssef et al. published in 2012, which included seven studies,
3 more single-center observational studies have been added to the literature, prompting an updated systematic review and meta-analysis. …